Seres Therapeutics Stock Market Value
| MCRB Stock | USD 0.73 0.08 9.88% |
| Symbol | Seres |
Seres Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Seres Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Seres Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Seres Therapeutics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Seres Therapeutics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Seres Therapeutics or generate 0.0% return on investment in Seres Therapeutics over 30 days. Seres Therapeutics is related to or competes with Syros Pharmaceuticals, Iovance Biotherapeutics, Veracyte, and Fate Therapeutics. Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are... More
Seres Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Seres Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Seres Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 26.87 | |||
| Value At Risk | (9.78) | |||
| Potential Upside | 10.0 |
Seres Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seres Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Seres Therapeutics' standard deviation. In reality, there are many statistical measures that can use Seres Therapeutics historical prices to predict the future Seres Therapeutics' volatility.| Risk Adjusted Performance | (0.0002) | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | (0.90) | |||
| Treynor Ratio | 2.03 |
Seres Therapeutics Backtested Returns
Seres Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0148, which indicates the firm had a -0.0148% return per unit of risk over the last 3 months. Seres Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Seres Therapeutics' Variance of 39.33, coefficient of variation of (8,493), and Risk Adjusted Performance of (0.0002) to confirm the risk estimate we provide. The entity has a beta of -0.0413, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Seres Therapeutics are expected to decrease at a much lower rate. During the bear market, Seres Therapeutics is likely to outperform the market. At this point, Seres Therapeutics has a negative expected return of -0.0943%. Please make sure to validate Seres Therapeutics' potential upside and the relationship between the accumulation distribution and price action indicator , to decide if Seres Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.31 |
Poor reverse predictability
Seres Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Seres Therapeutics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Seres Therapeutics price movement. The serial correlation of -0.31 indicates that nearly 31.0% of current Seres Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.31 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Seres Therapeutics lagged returns against current returns
Autocorrelation, which is Seres Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Seres Therapeutics' stock expected returns. We can calculate the autocorrelation of Seres Therapeutics returns to help us make a trade decision. For example, suppose you find that Seres Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Seres Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Seres Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Seres Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Seres Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Seres Therapeutics Lagged Returns
When evaluating Seres Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Seres Therapeutics stock have on its future price. Seres Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Seres Therapeutics autocorrelation shows the relationship between Seres Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Seres Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Seres Therapeutics Correlation, Seres Therapeutics Volatility and Seres Therapeutics Alpha and Beta module to complement your research on Seres Therapeutics. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Seres Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.